Sykehusinnkjøp HF intends, on behalf of the four regional health authorities, to enter into a framework agreement with Teva Norway AS from and including 1 May 2025 on the delivery of the medicine Riluzol Actavis soluble …
tablets for the treatment of the disease amyotrophic lateral sclerosis (ALS). ALS is a rare progressive nerve disease that causes gradual wastage of motor nerves in the cerebral cortch and spinal cord. There is no treatment that can cure the disease, but there is one registered medicine that can giv
e prolonged survival for this patient group. Reasons for awarding the contract without a competition notice: The manufacturer of the original medicine (Sanofi) notified Sykehusinnkjøp HF in April 2024 that they will stop the production of R